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ABSTRACT
Expression and function of the transcription factor
Sox10 is predominant in neural crest cells, its deri-
vatives and in oligodendrocytes. To understand how
Sox10 expression is regulated during development,
we analysed the potential of evolutionary conserved
non-coding sequences in the Sox10 genomic region
to function as enhancers. By linking these sequences
to a b-galactosidase marker gene under the control
of a minimal promoter, five regulatory regions were
identified that direct marker gene expression in
transgenic mice to Sox10 expressing cell types and
tissues in a defined temporal pattern. These possible
enhancers of the Sox10 gene mediate Sox10 expres-
sion in the otic vesicle, in oligodendrocytes and in
several neural crest derivatives including the devel-
oping peripheral nervous system and the adrenal
gland. They furthermore exhibit overlapping activities
and share binding sites for Sox, Lef/Tcf, Pax and AP2
transcription factors. This may explain high level and
robustness of Sox10 expression during embryonic
development.
INTRODUCTION
The transcription factor Sox10 is an important, pleio-
tropic regulator of neural crest and oligodendrocyte devel-
opment in all vertebrate species so far analysed (1–7). It
functions in stem cell maintenance (8), in several speci-
ﬁcation events (3,9) and during later phases of cell lineage
progression including terminal diﬀerentiation (10–12).
Much sparser is the information about the factors that
determine the spatiotemporal expression pattern of Sox10.
In the neural crest, Sox10 expression is under the control
of several extrinsic signals, such as BMPs, Wnts and FGFs
(1,5,8). With regards to intrinsic signals, there is evidence
that the related transcription factor Sox9 as well as FoxD3
are genetically upstream of Sox10 in the neural crest (13),
while Sox9 and Olig2 appear to be involved in Sox10
gene induction in cells of the oligodendrocyte lineage
(14–16). Whether these transcription factors inﬂuence
Sox10 expression directly, is not clear at the moment and
requires the identiﬁcation of cis-acting sequences in the
Sox10 genomic region.
BAC transgenic studies have shown that a genomic
region encompassing  65kb upstream as well as 55kb
downstream of the Sox10 gene are suﬃcient to reproduce
the main features of Sox10 expression during embryonic
development (17,18). Most of the important cis-acting
elements furthermore appear to be localized in enhancers
rather than the promoter region as the promoter failed to
direct marker gene expression to most of the typical Sox10
expression sites (17).
The fact that coding exons and intervening introns
could be removed from the Sox10 locus without sig-
niﬁcant alterations of the embryonic Sox10 expression
pattern (9,19,20) argues that the major enhancers are
localized to extragenic rather than intragenic regions. The
existence of at least two such enhancers was recently
proven in transgenic studies (17,21). Fortuitous deletion of
genomic sequences from a Sox10-containing BAC trans-
gene showed that important enhancer activity was
localized in a 20–30kb genomic interval upstream of the
Sox10 promoter sequences and that this enhancer activity
was strengthened by a second activity located in a
25–35kb region further upstream (17). The latter region
overlaps with a 16kb deletion 47kb upstream of the Sox10
gene which was generated by random insertion of a
transgene into the Sox10 genomic region and had been
found to cause partial depigmentation and colonic
aganglionosis in the corresponding mouse mutant (21).
Using bioinformatics, both studies have also detected
several highly conserved sequence elements within the
respective genomic intervals and postulated that these
elements may possess enhancer activity (17,21). None of
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the developing mouse embryo, and only one (alternatively
named DCHCS-1 and MCS6) has been experimentally
studied in cell culture and found to have enhancer activity
in cultured melanocytes (21).
Here, we use mouse transgenesis to identify enhancer
activity of evolutionary conserved non-coding sequences
in the Sox10 genomic region in vivo. We have focused on
those non-coding sequences that are conserved among
amniotes and at the same time located in the genomic
interval previously shown to be suﬃcient for the major
aspects of Sox10 expression. Some of these sequences
indeed functioned as cell type-speciﬁc enhancers and are
good candidates for bona ﬁde cis-acting gene regulatory
elements of the Sox10 gene.
MATERIALS AND METHODS
Construction of transgeneand generation oftransgenic
animals
Evolutionary conserved sequences U1, U2, U3, U4, U5,
D6 and D7 (Figure 1A) were ampliﬁed with  0.15kb
ﬂanking sequences on each side (Figure 1C) from 129Sv
mouse genomic DNA and inserted between SpeI and NotI
sites of pBKS-hsp68-lacZ such that the evolutionary
conserved sequences were placed immediately upstream
of the hsp68-lacZ cassette (22). Each evolutionary
conserved sequence was inserted separately. U3 and U4
were additionally cloned in combination upstream of the
hsp68-lacZ cassette. The hsp68-lacZ cassette was located
between HindIII and KpnI sites of pBKS (Figure 1B). The
transgenes were separated from the vector backbone by a
digest with SpeI and KpnI or NotI and KpnI, puriﬁed,
and microinjected into the male pronucleus of fertilized
FVB oocytes. Transgenic mice were generated from
injected oocytes according to standard techniques.
Founder mice and transgenic oﬀspring were identiﬁed
and genotyped by PCR analysis of DNA prepared from
tail biopsies using a combination of the common
reverse primer 50-AGTAGCTGTCAGCGTCTGGT-30
with one of the following transgene speciﬁc forward
primers: 50-GTAGGCCACAGGACATCAAC-30 for U1,
50-GGCACAGAAAGGTCTCTTTG-30 for U2, 50-GAG
CCCTGCTCATAAACAAG-30 for U3, 50-ACTGCGAC
TCTGCTGTCTCT-30 for U4, 50-GCACTCCTCTAT
GCCT CAAG-30 for U5, 50-ATTCAGAGGAAGGCC
AGAGG-30 for D6 and 50-AGAAGGCAGCTGAGGT
GTCT-30 for D7.
Sox10
lacZ/+ mice in which Sox10 coding sequences have
been replaced on one allele by lacZ marker sequences have
beenpreviouslygenerated(9).Inthese mice, b-galactosidase
expression reproduces the full pattern of Sox10 expression.
Tissue preparation, histological staining,
immunohistochemistry anddocumentation
Embryos from 9.5 days post coitum (d.p.c.) to 16.5d.p.c.
were obtained from staged pregnancies and underwent
ﬁxation in 1% or 4% paraformaldehyde depending on
their further usage. After ﬁxation, embryos were immedi-
ately stained for b-galactosidase activity or were
cryoprotected in sucrose and frozen at  808C in Tissue
Tec in preparation for cryotome sectioning.
Detection of b-galactosidase activity was performed
after ﬁxation in 1% paraformaldehyde on whole mount
embryos (9.5 and 11.5d.p.c.), isolated embryonic organs
(16.5d.p.c.) or 20mm transverse cryosections (16.5d.p.c.)
by incubation in 1% X-gal for several hours at 378C.
For immunohistochemistry, 10mm cryotome sections
from the forelimb level of genotyped, age-matched mouse
embryos were used with the following primary antibodies:
anti-b-galactosidase goat antiserum (1:500 dilution,
Biotrend), anti-BFABP rabbit antiserum, (1:10000 dilu-
tion, gift of C. Birchmeier and T. Mu ¨ ller, MDC, Berlin),
anti-Olig2 rabbit antiserum (1:50000 dilution, gift of
D. Rowitch, UCSF, San Francisco), anti-Brn3.0 rabbit
antiserum (1:2000 dilution, gift of Dr E. Turner, UCSD,
San Diego), anti-Oct-6 rabbit antiserum [1:2000 dilution,
(23)], anti-Lmx1b guinea pig antiserum (1:15000 dilution,
gift of C. Birchmeier and T. Mu ¨ ller, MDC, Berlin), anti-
Sox10 guinea pig antiserum [1:2000 dilution, (24)].
Secondary antibodies conjugated to Cy2 and Cy3 immu-
noﬂuorescent dyes (Dianova) were used for detection.
Samples were analysed and documented either with a
Leica (Bensheim, Germany) inverted microscope
(DMIRB) equipped with a cooled MicroMax CCD
camera (Princeton Instruments, Trenton, NJ) or with a
Leica MZFLIII stereomicroscope equipped with an
Axiocam (Zeiss, Oberkochem, Germany).
Cellculture, transient transfection, extract preparation
andEMSA
HEK293 cells were maintained in Dulbecco’s Modiﬁed
Eagle’s Medium (DMEM) containing 10% fetal calf
serum (FCS) and transfected by the calcium phosphate
technique using 10mg plasmid DNA per 100mm plate.
Transfected plasmids contained expression cassettes for
HA-tagged Sox9 (amino acids 1–190), HA-tagged Sox10
(amino acids 1–189) (12), T7-tagged Pax3 (25), T7-tagged
AP2a (gift of H. Schorle, Bonn) and HA-tagged Lef1
(gift of J. Behrens, Erlangen) under the control of the
cytomegalovirus immediate early promoter.
Forty-eight hours post transfection, cells were harvested
for extract preparation (26) and ectopic expression of the
respective transcription factor was veriﬁed by western
blotting using anti-HA tag (1:200 dilution, hybridoma
supernatant,clone 12CA5)or anti-T7 tag (1:10000 dilution,
Novagen) mouse monoclonals. With these extracts, electro-
phoretic mobility shift analyses (EMSA) were performed in
the presence of poly(dGdC) as unspeciﬁc competitor in the
case of Sox9, Sox10 and Lef1 or in the presence of
poly(dIdC) in the case of Pax3 and AP2a using
32P-labelled
fragments from the evolutionary conserved regions with
a size between 69 and 121bp (Figure 7A) (16).
RESULTS
TheSox10 genomicregioncontainssevennon-coding regions
that areevolutionary conserved inmammals and birds
Sequence comparisons among orthologous genomic
regions of mammalian and other vertebrate species have
Nucleic Acids Research, 2007, Vol. 35, No. 19 6527Figure 1. Characterization of evolutionary conserved non-coding sequences from the Sox10 genomic region and generation of transgenic lines
containing these sequences. (A) Localization of seven ECR (U1, U2, U3, U4, U5, D6, D7, shown in red) in the Sox10 genomic interval on mouse
chromosome 15 relative to Sox10 and the adjacent Polr2f and Pick1 genes (in blue). Sequence conservation among various mammalian species and
chicken is evident from multiple sequence alignments. (B) Design of the transgenic constructs consisting of one of the seven ECR, the hsp68 minimal
promoter (Hsp), the b-galactosidase marker gene (bGal) and a SV40 polyA signal (pA). (C) Position of each of the seven ECR in the mouse genome
(Mm8), their lengths, conservation to chicken and man as well as the exact coordinates of the fragment present in the transgenic constructs.
(D) Summary of independent founders obtained for each transgenic construct, resulting transgenic lines and their overall properties of transgene
expression.
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coding regions (ECR) that have an increased likelihood
to function as transcriptional regulatory regions (27).
Many of these regions are located in the vicinity of
genes that code for important developmental regulators
(28). Taking into account that Sox10 is such an important
regulator and that its functions are highly conserved
in vertebrate embryogenesis (29,30), comparative geno-
mics should be suited to identify the gene’s regulatory
regions.
We concentrated on the genomic interval previously
shown by BAC transgenesis to reproduce the main
features of embryonic Sox10 expression (18). Using the
ECR browser (http://ecrbrowser.dcode.org) and the
human sequence as the base genome, we identiﬁed seven
regions around the Sox10 gene that exhibited a greater
than 70% sequence identity over at least 100bp in
comparison with the chicken genome (Figure 1A). Five,
termed U1–U5, were localized in front of the Sox10 gene,
two, called D6 and D7, were behind the gene. U1
corresponds to MCS6/DCHCS-1 in previous studies,
U2 to MCS4, U3 to MCS3 and U4 to MCS2 (17,21).
U5, D6 and D7 have not been described so far. Their
length varied between 150 and 400bp (Figure 1C). In
comparisons between the mouse and chicken genome,
these regions exhibited at least 67% identity over their
whole length (Figure 1C and Supplementary Figures 1–6).
Between mouse and human genome, the sequence
identity was greater than 89% and there was additional
strong sequence conservation in the ﬂanking sequences.
Both the lower sequence conservation and the shorter
length in evolutionary distant species as compared to
evolutionary close species has similarly been observed in
a previous whole genome study (31). In contrast to this
strong sequence conservation among mammals and
between mammals and chicken, none of these regions
exhibited a signiﬁcant degree of conservation in
Xenopus laevis, Danio rerio or Fugu rubripes. The
conservation of the identiﬁed regions is thus restricted
to amniotes.
ECR of theSox10 genomic regionacquire their gene
regulatory activity at differenttimes ofembryogenesis
To experimentally address the capacity of these seven
evolutionary conserved regions to function as regulatory
regions of the Sox10 gene, we cloned each element in
front of a hsp68-lacZ cassette (Figure 1B) in which
b-galactosidase expression is under the control of the
hsp68 minimal promoter (22). We chose the hsp68
promoter because it has been extensively used in trans-
genic studies and has been shown to have no detectable
basal activity in transgenic embryos (22).
We injected each construct in fertilized oocytes to
generate transgenic lines. For each transgenic construct, at
least two independent founders were obtained that stably
transmitted the transgene to their oﬀspring (Figure 1D).
Transgenic progeny were collected at several stages of
embryonic development followed by X-gal staining for the
detection of the b-galactosidase transgene. Identical
staining times were used for all transgenic embryos of a
given age to obtain an approximation of the relative
strength of transgene expression. Unless otherwise stated,
staining patterns were highly reproducible between
diﬀerent lines of the same transgenic construct. Only
staining intensity varied somewhat between the lines as a
result of diﬀerences in copy number and integration site.
Age-matched Sox10
lacZ/+ embryos were stained in parallel
to allow comparison with the regular Sox10 expression
pattern (9).
At 9.5d.p.c., Sox10 expression is visible in the
frontonasal process, the otic vesicle, the cranial ganglia
and branchial arches, in forming dorsal root ganglia
(DRG) and sympathetic ganglia and further caudal in
emerging neural crest cells (Figure 2A). A weak staining
was also detected at the mid-hindbrain boundary.
Transgenic embryos fell into one of three categories at
9.5d.p.c. Embryos carrying the U4, U5 or D7 transgene
constituted one such category (Figure 2E, F and H).
In this group, b-galactosidase staining and thus transgene
expression was undetectable.
The second group consisted of embryos carrying the U2
or D6 transgene, and is characterized by a very restricted
b-galactosidase expression pattern that corresponded to
select parts of the Sox10 expression pattern (Figure 2C
and G). The D6 transgene, for instance, was strongly
expressed only in otic vesicle, trigeminal, facial and
acoustic ganglia (Figure 2G). Very light b-galactosidase
staining was additionally detected in the DRG area. DRG
exhibited a much stronger b-galactosidase staining for the
U2 transgene (Figure 2C). This staining decreased
caudally in a manner similarly observed for the
Sox10
lacZ allele (Figure 2A). Other expression sites for
the U2 transgene include the cranial ganglia, with
particularly strong expression in the trigeminal, facial
and acoustic ganglia (Figure 2C). Branchial arches and
otic vesicle, in contrast, did not express the U2 transgene,
and only very few cells were positive for U2 transgene
expression in the frontonasal process.
The ﬁnal category consisted of U1 and U3 transgenic
embryos in which transgene expression reproduced
most of the Sox10 expression pattern (Figure 2B and
D). In U1 transgenic embryos, all Sox10 expressing tissues
were b-galactosidase positive with exception of the mid-
hindbrain boundary (Figure 2B). For most tissues,
expression levels were, however, signiﬁcantly lower than
in the Sox10
lacZ/+ embryos. Only the otic vesicle appeared
strongly stained in all U1 transgenic lines.
The otic vesicle was the sole site of Sox10 expression
that did not express the U3 transgene at 9.5d.p.c.
(Figure 2D). For all other Sox10 expressing tissues,
b-galactosidase staining was visible in U3 transgenic
embryos. In the trunk region, it appeared more intense
than the corresponding staining for U1 transgenic
embryos (compare Figure 2D with B). The frontonasal
process was only weakly stained by b-galactosidase
activity in U3 transgenic embryos. Notably, U3 transgenic
embryos also exhibited b-galactosidase staining at several
sites where Sox10 expression does not normally occur,
including cells in the heart. However, even this ectopic
b-galactosidase staining was highly reproducible between
the diﬀerent U3 transgenic lines.
Nucleic Acids Research, 2007, Vol. 35, No. 19 6529Figure 2. Detection of b-galactosidase transgene expression in embryos at 9.5 and 11.5d.p.c. b-Galactosidase activity was detected colorimetrically
using X-gal substrate at 9.5 dpc (A–H) and at 11.5d.p.c. (I–P)i nSox10
lacZ/+ (A, I) and age-matched embryos carrying a hsp68-lacZ transgene
driven by one of the following ECR from the Sox10 genomic region: U1 (B, J), U2 (C, K), U3 (D, L), U4 (E, M), U5 (F, N), D6 (G, O) and D7
(H, P). Transgenic embryos were stained in parallel for 9h, Sox10
lacZ/+ embryos for 3h. No b-galactosidase staining was detected in wildtype
littermates under the conditions applied. cg, cranial ganglia; DRG, dorsal root ganglia; ov, otic vesicle; ba, branchial arches; h, heart.
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region converge during mid-embryogenesis
At 11.5d.p.c., expression of the various transgenes
had undergone a number of signiﬁcant changes.
b-Galactosidase staining in the branchial arches and the
frontonasal process was no longer visible in transgenic
embryos (Figure 2J–P). In age-matched Sox10
lacZ/+
embryos, b-galactosidase staining had similarly disap-
peared from the branchial arches and was strongly
decreased in the frontonasal process (Figure 2I) arguing
that extinction of transgene expression recapitulates
downregulation of Sox10 in these areas.
U1, U2, U3 and D6, the four transgenes that were
already expressed at 9.5d.p.c., still exhibited an intense
b-galactosidase staining (Figure 2J–L and O). This was
particularly strong throughout the developing peripheral
nervous system including ganglia as well as nerves.
Intriguingly, the staining pattern for the U1, U2, U3
and D6 transgenic embryos resembled each other much
more than they did at earlier times arguing that these four
evolutionary conserved non-coding sequences overlap
signiﬁcantly in their gene regulatory activity at this
embryonic age.
Nevertheless, closer inspection revealed minor, but
clear diﬀerences among U1, U2, U3 and D6 transgenic
embryos. Compared to U1, U3 and D6 transgenic
embryos, U2 transgenic embryos had consistently lower
b-galactosidase staining in the cranial ganglia (compare
Figure 2K with J, L and O). U1 and U2 transgenic
embryos furthermore exhibited intense b-galactosidase
staining in both DRG and nerves (Figure 2J and K),
whereas staining in U3 transgenic embryos was more
pronounced along the nerves (Figure 2L). D6 transgenic
embryos in contrast showed preferential b-galactosidase
staining in DRG (Figure 2O). Signiﬁcant expression in
cells of the enteric nervous system was only observed for
the U1 and U3 transgenes.
Expression in the otic vesicle was consistent with
observations on 9.5d.p.c. in that U2 and U3 transgenic
embryos did not exhibit b-galactosidase staining in this
structure (Figure 2K and L). For U1 transgenic embryos,
b-galactosidase staining in the otic vesicle was still
detectable but much less pronounced than at 9.5d.p.c.
arguing that U1 activity is already downregulated at
11.5d.p.c. (Figure 2J). D6 activity, in contrast, was still
high according to the strong b-galactosidase staining in
D6 transgenic embryos at 11.5d.p.c. (Figure 2O).
Of the three ECR that had not exhibited gene
regulatory activity in transgenic embryos at 9.5d.p.c.,
U5 now started to become detectable in the trigeminal
ganglion and in DRG arguing that U5 obtains gene
regulatory activity later than U1, U2, U3 and D6
(Figure 2N). Additional U5 expression was observed
in the dorsal spinal cord. Although also detected in D6
transgenic embryos (compare Figure 2N with O), the
dorsal spinal cord is not a main expression site of Sox10.
U4 and D7 transgenic embryos, in contrast, failed to
produce any b-galactosidase staining under standard
staining procedures. Even under signiﬁcantly prolonged
staining times, no b-galactosidase activity was detectable
in D7 transgenic embryos at 11.5d.p.c. or any other earlier
or later time during embryonic development including
18.5d.p.c. This was also the case for embryos derived from
ﬁve out of seven U4 transgenic lines. In contrast, embryos
from one U4 transgenic line developed weak midline
staining, whereas embryos from yet another U4 founder
showed blood vessel staining upon extended staining times
(data not shown). We believe that this weak staining is
rather indicative of the site at which transgene integration
occurred in the respective U4line than of bona ﬁde gene
regulatory activity of U4. In embryos, in which the hsp68-
lacZ cassette was under the simultaneous control of U3
and U4, transgene expression was both quantitatively as
well as qualitatively identical to U3 transgenic embryos
(data not shown). This corroborates the absence of any
enhancer activity in U4 and at the same time argues
against a general silencer activity of this evolutionary
conserved sequence element. In summary, we failed to
detect any consistent gene regulatory activity for the
non-coding regions U4 and D7 despite their evolutionary
conservation.
Gene regulatory activities of theECR in theSox10 genomic
region divergeagain during laterstages of embryogenesis
b-Galactosidase expression in the various transgenic lines
had not changed dramatically from 11.5 to 12.5d.p.c.
Within the developing peripheral nervous system, the U1,
U2 and U3 transgenes were all still expressed in peripheral
nerves (Figure 3A–C), whereas DRG expression was
detected for U1, U2, U5 and D6 (Figure 4A–D). Those
cells that expressed the b-galactosidase transgene under
control of the U1, U2 or U3 element in peripheral nerves
or ganglia also contained Sox10 (Figures 3A–C and 4A, B)
and the early glial marker BFABP (Figure 4E, F and data
not shown), but not the neuronal marker Brn3.0
(Figure 4I and J) indicating that transgene expression
reﬂects expression of the endogenous Sox10 even at the
cellular level. In contrast, b-galactosidase-positive cells in
DRG of U5 or D6 transgenic lines did not colabel with
Sox10 or glial markers (Figure 4C, D, G and H), but
rather with neuronal markers (Figure 4K and L).
At 16.5d.p.c., b-galactosidase-positive cells had com-
pletely disappeared from DRG in D6 transgenic embryos
(Figures 4P, U, Y and 5F). Although a fraction of sensory
neurons within DRG still expressed the U5 transgene
(Figure 4X), the overall b-galactosidase staining intensity
had also dramatically decreased in DRG of U5 transgenic
embryos (Figures 4O, T, X and 5E). Only DRG from U1
and U2 transgenic embryos still exhibited signiﬁcant
b-galactosidase staining at 16.5d.p.c. (Figure 5B and C).
Similar to DRG of age-matched Sox10
lacZ/+ embryos,
b-galactosidase was furthermore exclusively localized to
Sox10- and BFABP-expressing satellite glia (Figure 4M,
N, R and S) and not to Brn3.0-expressing sensory neurons
(Figure 4V and W).
Strong b-galactosidase staining was also observed for
the peripheral nerves in embryos from the U1, U2, U3 and
D6 transgenic lines (Figure 5B–D and F). Whereas U1,
U2 and U3 transgenes were already expressed in the
peripheral nerve at 12.5d.p.c., D6 transgene expression
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Figure 4A–C with D). For all four transgenic lines,
b-galactosidase was furthermore found in cells that
express Sox10 as well as Oct6 (Figure 3E–L) arguing
that the transgene in all four lines is properly expressed in
Schwann cells.
By b-galactosidase staining, sympathetic ganglia were
found to still express U1, U2 and D6 transgenes at
16.5d.p.c., whereas the diﬀerentiating enteric nervous
system and the medulla of the adrenal gland expressed
b-galactosidase predominantly in the U1 and U3 trans-
genic lines (Figure 1D and data not shown).
Very little b-galactosidase staining was observed for
most transgenic lines in the spinal cord at 16.5d.p.c.
In particular, the dorsal spinal cord expression observed
for the U5 and D6 transgenic lines at 11.5d.p.c. had
mostly disappeared (Figure 5E and F). Only U2 and U3
transgenic embryos exhibited signiﬁcant spinal cord
expression (Figure 5C and D). In case of the U2 transgenic
line, b-galactosidase-positive cells were scattered through-
out the spinal cord parenchyma at 16.5d.p.c. as expected
for oligodendrocyte progenitors and observed in the
age-matched Sox10
lacZ/+ embryos (compare Figure 5C
with A). Co-immunohistochemistry with Sox10 and Olig2
conﬁrmed that the b-galactosidase expressing cells in the
U2 transgenic line were oligodendroglial cells (Figure 6A
and B). In contrast, b-galactosidase-positive cells in the
U3 transgenic line were predominantly localized in the
dorsal horn (Figure 5D) and expressed interneuron
markers such as Lmx1b, but not Sox10 (Figures 5D and
6C, D). U2 is therefore the only identiﬁed evolutionary
conserved non-coding sequence with regulatory activity in
oligodendroglia.
Overlappinggeneregulatoryactivitiesarereflectedbyshared
patterns of transcription factorbinding in theECR
Despite the fact that several of the evolutionary conserved
sequences exhibited overlapping enhancer activities in the
early neural crest and several neural crest derivatives,
we failed to detect any meaningful sequence similarities
between these sequences by various bioinformatics
approaches (data not shown). However, we found
common binding motifs for transcription factors. Using
the rVista2.0 program (http://rvista.dcode.org), numer-
ous, well-conserved transcription factor binding sites were
detected in all putative enhancers (Supplementary
Figures 1–5). Those for U1, U2 and U3 have already
been listed previously (17). Among them, binding sites for
caudal-type homeodomain proteins, Sox proteins, Tcf/Lef
proteins and Stat proteins were present in all enhancers
with strong neural crest activity, i.e. U1, U2, U3 and D6.
U1 and U3 as enhancers with particularly high expression
in the early neural crest additionally carried potential
binding sites for forkhead domain proteins, ikaros-type
zinc ﬁnger proteins and engrailed-type homeodomain
proteins. However, the relative arrangement of shared
transcription factor binding sites was diﬀerent in each
enhancer.
Figure 3. Cellular expression pattern of b-galactosidase transgenes in peripheral nerves. Co-immunohistochemistry was performed on spinal nerves
of embryos at 12.5d.p.c. (A–D) and 16.5d.p.c. (E–L) using antibodies directed against b-galactosidase (in green) in combination with
antibodies directed against Sox10 (A–H) or Oct6 (I–L) (all in red). The embryos carried a hsp68-lacZ transgene driven by either the U1 (A, E, I),
the U2 (B, F, J), the U3 (C, G, K) or the D6 (D, H, L) region.
6532 Nucleic Acids Research, 2007, Vol. 35, No. 19Figure 4. Cellular expression pattern of b-galactosidase transgenes in DRG. Co-immunohistochemistry was performed on DRG of embryos
(forelimb level) at 12.5d.p.c. (A–L) and 16.5d.p.c. (M–Y) using antibodies directed against b-galactosidase (in green) in combination with antibodies
directed against Sox10 (A–D, M–P), BFABP (E–H, R–U) or Brn3.0 (I–L, V–Y) (all in red). The embryos carried a hsp68-lacZ transgene driven by
either the U1 (A, E, I, M, R, V), the U2 (B, F, J, N, S, W), the U5 (C, G, K, O, T, X) or the D6 (D, H, L, P, U, Y) region.
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roles in neural crest development directly for their ability
to bind to the evolutionary conserved non-coding
sequences (Figure 7). For EMSA, evolutionary conserved
non-coding sequences were divided in subfragments that
still allowed a good resolution of protein complexes after
gel electrophoresis (Figure 7A). The tested transcription
factors were Sox9, Sox10, Pax3, AP2a, Lef1, FoxD3
and Slug. With exception of the hind part of U2
(Figure 7E), all fragments bound at least one of the
analysed transcription factors. None of the enhancers
showed binding of FoxD3 and Slug (data not shown),
only U3 and U5 bound AP2a(Figure 7I andK) and all had
at least one binding site for Sox9, Sox10, Pax3 and Lef1
(Figure 7B–D and F–M). Binding was veriﬁed by super-
shift of the obtained complex with antibodies directed
against the tag fused to each transcription factor (data not
shown).
U1, U3 and D6 which are all enhancers with high neural
crest activity possessed multiple binding sites for Sox
proteins, Pax3 and Lef1 (Figure 7B, C, F–I, L and M). U2
which has also signiﬁcant activity in the neural crest and
its derivatives similarly has multiple Sox protein and Lef1
binding sites, but only a single Pax3 site (Figure 7D). In
case of the Sox binding sites, some bound Sox protein
dimers (Figure 7B–D, F, G, I, L and M), others bound
monomeric Sox9 or Sox10 (Figure 7D and H) in accord
with previous observations on other regulatory regions
controlled by these proteins (30).
U5, in contrast, exhibits only weak neural crest
expression. Correspondingly, it contained only a single
dimeric Sox10-binding site, a single Pax3 and single Lef1
binding site in addition to its AP2a-binding site (Figure 7J
and K). Thus, it appears that the evolutionary conserved
non-coding sequences bind a similar set of neural crest-
related transcription factors and that the number of
binding sites within each element corresponds to the
activity of each region within neural crest cells and their
derivatives.
DISCUSSION
Over the last couple of years, a number of studies have
shown that evolutionary conserved non-coding sequences
in the vicinity of a gene are good candidates for the gene’s
regulatory regions (27,28). By applying this strategy to the
Sox10 chromosomal region, we here identify ﬁve regions
that have the capacity to direct transgene expression in
tissues of mouse embryos in which Sox10 is normally
expressed. Taking furthermore into account that Polr2f
and Pick1, the two genes ﬂanking the Sox10 genomic
Figure 5. Detection of b-galactosidase transgene expression in embryos at 16.5d.p.c. b-Galactosidase activity was detected colorimetrically using
X-gal substrate on transverse sections from the forelimb level of Sox10
lacZ/+ (A) and age-matched embryos carrying a hsp68-lacZ transgene driven
by one of the following ECR from the Sox10 genomic region: U1 (B), U2 (C), U3 (D), U5 (E) and D6 (F). Embryo sections were stained in parallel
for 2h. No b-galactosidase staining was detected in wildtype littermates under the conditions applied.
Figure 6. Cellular expression pattern of b-galactosidase transgenes in
the embryonic spinal cord. Co-immunohistochemistry was performed
on transverse sections of the embryonic spinal cord (forelimb level) at
16.5d.p.c. using antibodies directed against b-galactosidase (in green) in
combination with antibodies directed against the cell-type speciﬁc
markers (in red) Sox10 (A, C), Olig2 (B) and Lmx1 (D). The embryos
carried a hsp68-lacZ transgene driven by the U2 (A, B) or the U3
(C, D) region.
6534 Nucleic Acids Research, 2007, Vol. 35, No. 19Figure 7. Binding of neural crest derived transcription factors to evolutionary conserved non-coding sequences from the Sox10 genomic region. (A)
Schematic representation of the fragments used for EMSA. The length of each fragment is given in bp. (B–M) Each of the radiolabeled fragments
shown in (A) was incubated with control extracts (C) or extracts containing Sox9, Sox10, Pax3, AP2a or Lef1 protein before protein-DNA complexes
were resolved from the unbound DNA by native gel electrophoresis. The unbound DNA is shown in the ﬁrst lane of each panel (-) and runs at the
bottom. Each panel represents the results from EMSA of a single fragment: (B) U1-1; (C) U1-2; (D) U2-1; (E) U2-2; (F) U3-1; (G) U3-2; (H) U3-3;
(I) U3-4; (J) U5-1); (K) U5-2; (L) D6-1; (M) D6-2.
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tionary conserved non-coding sequences are good candi-
dates for Sox10 gene enhancers. Similar to its close
relative Sox9 (32,33), the Sox10 gene thus appears to be
regulated by numerous enhancers that are distributed over
large genomic regions.
The regulatory activity of the identiﬁed Sox10 enhan-
cers and their relative position to the Sox10 gene are also
consistent with previous BAC transgene deletion studies
(17). These studies found that deletion of most sequences
upstream of the Sox10 promoter only leaves a weak
residual Sox10 expression. On the basis of our study, most
of this residual expression is likely mediated by D6 which
was still present in the BAC deletion mutant, whereas
U1, U2, U3 and possibly U5 were absent. The presence of
20–30kb of additional upstream sequences in two further
BAC deletion mutants led to the recovery of Sox10
expression, albeit at reduced levels (17). This interval
contained U3 and possibly U5 so that the enhancer
activities of these two elements are likely responsible for
the observed recovery. Not contained, however, were U1
and possibly U2 arguing that the absence of these two
enhancers in the BAC deletion mutants caused the
quantitative diﬀerence to wildtype Sox10 expression
levels.
In contrast to many other genes for key developmental
regulators including Sox9 (28,32,34,35), non-coding
sequences in the vicinity of the Sox10 gene are not
conserved in all vertebrate species. The evolutionary most
distant conservation is between mammals and chicken. No
obvious sequence homologies in the Sox10 chromosomal
region were obtained with Xenopus or zebraﬁsh, although
Sox10 similarly functions as a key regulator of neural crest
development in all vertebrates (1–7). Interestingly, expres-
sion of the group B1 Sox genes Sox2 and Sox3 is also
regulated by enhancer regions that are conserved in
amniotes but not other vertebrates despite the crucial
roles of these two genes in early embryogenesis and
neurogenesis of all vertebrates (36,37).
The absence of evolutionary conserved Sox10 gene
enhancers between mammals and ﬁsh agrees with previous
experimental data. Whereas few kilobases of the zebraﬁsh
Sox10 upstream region allowed eﬃcient expression in
melanoblasts and oligodendroglial cells, this was not the
case in mammals (17,38,39). Our results thus argue that
there is not always a strict correlation between the
conservation of a gene’s function during development
and the conservation of its regulatory elements. This has
also been observed for a few other genes, most promi-
nently for c-Ret (40).
In contrast to many other published cases where each
regulatory element contributes a highly speciﬁc temporal
or spatial aspect to the overall expression pattern of a gene
(28,41,42), the regulatory elements of the Sox10 gene have
overlapping activities. U1, U2, U3 and D6 are all
simultaneously active at 11.5d.p.c. in the developing
peripheral nervous system or at 16.5d.p.c. in Schwann
cells of peripheral nerves. These overlapping activities are
also reﬂected by the fact that similar combinations of
transcription factors bind to U1, U2, U3 and D6. In
particular, the presence of multiple binding sites for Sox
proteins, Pax3 and Lef1 appears to be a hallmark of these
enhancers. These sites may mediate eﬀects of canonical
Wnt signalling on Sox10 expression, Sox9-dependent
induction and Sox10 autoregulation (1,5,13).
Sox10 expression in a particular tissue or cell type
during embryonic development thus very often is the
result of the composite activity of many enhancers. In this
respect, regulation of Sox10 expression resembles closely
the regulation of Sox2 expression in the developing neural
tube (37).
Despite overlapping activity, there are also clear
diﬀerences between the various enhancers. In Schwann
cells, U1, U2 and U3 are, for instance, continuously active
over a prolonged period, whereas D6 activity in peripheral
nerves is interrupted. The fact that some regulatory
regions show a continuous activity in a certain cell type,
whereas others exhibit a more dynamic pattern may
indicate that these regulatory regions are at least partly
under control of diﬀerent signals. Nevertheless, the
simultaneous activity of many enhancers in the same cell
type may be valuable as a fail-safe mechanism that
guarantees continued Sox10 expression even upon inacti-
vation or deletion of a particular regulatory region.
In case of Sox10, each regulatory region determines
multiple aspects of the expression pattern. U2, for
instance, drives Sox10 expression in satellite glia and
oligodendroglial cells at the same time when it directs
expression in Schwann cells. This contrast with other
genes where the activity of a deﬁned enhancer often
correlates with expression in a certain cell type or tissue
(28,41,42).
Several evolutionary conserved non-coding sequences
also exhibited ectopic expression in our study. Some of
this ectopic activity was clearly due to integration site
eﬀects as in the case of U4 where weak blood vessel or
midline activity was detected selectively in the progeny of
a single founder. In other cases, ectopic activity was
reproducibly observed in all available founders. Thus U3
activity was present in the heart, and the dorsal spinal
cord exhibited U3 and U5 activity at distinct phases of
embryonic development. Additionally, some of the evolu-
tionary conserved non-coding sequences were found to
direct neuronal expression, although glia are the only
diﬀerentiated cells in the nervous system that normally
express Sox10 (9). These sites of ectopic activity very often
correspond to cell types or tissues that originate from
Sox10 expressing precursors (e.g. cardiac neural crest,
progenitors to sensory neurons in DRG) or exhibit a very
transient expression of low amounts of Sox10 (e.g. the
dorsal spinal cord). It thus appears that the activity of
some of the identiﬁed regulatory regions is not properly
turned oﬀ when they are studied outside their normal
genomic context.
The Sox10 genomic region therefore likely contains
additional elements that help to restrict Sox10 expression
during embryonic development in time and in space. Due
to the design of our study, these regulatory activities
would have escaped our detection. As a consequence, we
should have found evolutionary conserved non-coding
sequences in our study without apparent activity. This was
indeed the case for U4 and D7 which may therefore
6536 Nucleic Acids Research, 2007, Vol. 35, No. 19function as negative regulatory elements. Whether these
elements really function as silencers, has to be tested in
future experiments. Our failure to detect U4-dependent
silencing of U3 activity certainly argues that these
elements could also have other less obvious functions.
The composite activity of the ﬁve identiﬁed evolution-
ary conserved non-coding sequences accounts for many
aspects of the Sox10 expression pattern, although this
does not exclude that there are more enhancers with
similar and redundant activity yet to be discovered. Not
reﬂected in the activity of the ﬁve evolutionary conserved
non-coding sequences is the normally observed expression
of Sox10 in the melanocyte lineage and in the early neural
crest when cells change from a premigratory to a
migratory state. Deal et al. reported that melanocyte
expression is at least in part conveyed by the promoter
region (17) which was not analysed in our study. The
localization of the regulatory element for the early neural
crest expression in contrast remains at large.
Interestingly, U1 had previously been implicated as
DCHCS-1 in the regulation of Sox10 expression (21).
Pigmentation defects and partial aganglionosis of the
colon in a mouse model of Waardenburg/Hirschsprung
disease had been attributed to random transgene insertion
47kb upstream of the Sox10 gene and concomitant
deletion of 16kb. As U1 is present in the deleted region
and exhibited enhancer activity in transfected melanocytic
cell lines, U1 was postulated to be the melanocyte
enhancer and possibly the enteric nervous system enhan-
cer lost during transgene insertion. Our results support the
role of U1 as an enteric nervous system enhancer. The link
between the loss of U1 and the observed pigmentation
defect in the mouse mutant is not as straightforward. Our
results rather argue for a more complex scenario in which
other regions deleted during transgene insertion, the
rearrangement itself, or functional interactions between
U1 and other regulatory regions contribute to the
observed melanocyte defect. In future studies, it will be
interesting to search for mutations or deletions in any of
the identiﬁed enhancers in patients who do not carry
mutations in the Sox10 coding region, but nevertheless
exhibit the typical symptoms such as Waardenburg/
Hirschsprung disease, peripheral neuropathies or central
leukodystrophies (43,44).
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